8,762 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,762 shares of the company’s stock, valued at approximately $201,000.

Other large investors have also added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. grew its stake in Amphastar Pharmaceuticals by 14.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company’s stock worth $400,000 after purchasing an additional 1,694 shares during the period. Picton Mahoney Asset Management grew its holdings in Amphastar Pharmaceuticals by 6,600.0% in the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company’s stock worth $46,000 after purchasing an additional 1,584 shares during the period. Graham Capital Management L.P. acquired a new stake in Amphastar Pharmaceuticals in the first quarter worth $766,000. Allspring Global Investments Holdings LLC increased its stake in Amphastar Pharmaceuticals by 9.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company’s stock valued at $434,000 after purchasing an additional 1,262 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Amphastar Pharmaceuticals in the first quarter valued at $532,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ AMPH opened at $24.52 on Monday. The stock has a market capitalization of $1.14 billion, a P/E ratio of 9.18 and a beta of 0.75. The company has a 50-day moving average price of $27.33 and a 200-day moving average price of $25.22. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $53.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21.

Wall Street Analyst Weigh In

AMPH has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 22nd. Zacks Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Bank of America lifted their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Friday. Finally, Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.60.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.